Article

Synthesis of 3-(Pyridin-2-yl)quinazolin-2,4(1*H*,3*H*)-diones via Annulation of Anthranilic Esters with *N*-pyridyl Ureas †

Svetlana O. Baykova, Kirill K. Geyl, Sergey V. Baykov and Vadim P. Boyarskiy *

Institute of Chemistry, Saint Petersburg State University, 7/9 Universitetskaya Nab., Saint Petersburg 199034, Russia; s.baykova@spbu.ru (S.O.B.); kirillgeyl@outlook.com (K.K.G.); s.baykov@spbu.ru (S.V.B.)
* Correspondence: v.boiarskii@spbu.ru
† In commemoration of the 300th anniversary of Saint Petersburg State University's founding.

Abstract: A new route for the synthesis of quinazolin-2,4(1*H*,3*H*)-diones and thieno [2,3-*d*]pyrimidine-2,4(1*H*,3*H*)-diones substituted by pyridyl/quinolinyl moiety in position 3 has been developed. The proposed method concluded in an annulation of substituted anthranilic esters or 2-aminothiophene-3-carboxylates with 1,1-dimethyl-3-(pyridin-2-yl) ureas. The process consists of the formation of *N*-aryl-*N*′-pyridyl ureas followed by their cyclocondensation into the corresponding fused heterocycles. The reaction does not require the use of metal catalysts and proceeds with moderate to good yields (up to 89%). The scope of the method is more than 30 examples, including compounds with both electron-withdrawing and electron-donating groups, as well as diverse functionalities. At the same time, strong electron-acceptor substituents in the pyridine ring of the starting ureas reduce the product yield or even prevent the cyclocondensation step. The reaction can be easily scaled to gram quantities.

Keywords: quinazoline-2,4-diones; thienopyrimidine-2,4-diones; pyridines; quinolines; ureas; anthranilic acids derivatives; annulation

1. Introduction

The quinazoline-2,4-dione fragment is part of many clinical candidates: selurampanel (an AMPA/kainate receptor antagonist for epilepsy treatment) [1,2], elinogrel (a P2Y12 receptor antagonist for the treatment of cardiovascular atherothrombotic disease) [3–5], zenarestat (an aldose reductase inhibitor for the management of diabetic peripheral neuropathy) [6,7], ketanserin (a 5-HT2 receptor antagonist with the hypotensive action) [8,9], carotegrast (α4 integrin antagonist for the treatment of ulcerative colitis) [10,11], senaparib (a PARP inhibitor for the therapy of solid tumors) [12–14], and BMS-986142 (a Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis) [15–17]. In addition, quinazoline-2,4-dione derivatives were recognized as inhibitors of several cancer-related enzymes [18] (including carbonic anhydrases IX and XII [19], histone deacetylase-6 [20], VEGFR-2 [21], tankyrases [22], aminopeptidase [23]) and as modulators of autoimmune processes [24–27]. Moreover, they are widely used to combat viral [28,29], bacterial [30–32], parasitic [33–35], and fungal [36] infections.

Thienopyrimidine-2,4-diones is another class of medicinally important annulated dicarbonyl heterocycles [37]. These compounds found application in the design of gonadotropin-releasing hormone receptor antagonists [38–43] and acetyl-CoA carboxylase inhibitors [44–46].

In agriculture, both scaffolds (quinazoline-2,4-diones and thienopyrimidine-2,4-diones) are employed for weed control [47,48].

Among the quinazoline and thienopyrimidine diones described in the literature, most of the compounds contain a substituent in position 3. The biological significance causes the emergence of a number of methods for the synthesis of 3-substituted quinazoline-2,4-diones, including (i) the treatment of 2-aminobenzamides with phosgene, (ii) the reaction of isatoic anhydride with amines or isocyanates, (iii) the condensation of 2-halobenzoates with

monoalkylureas, (iv) Baeyer–Villiger oxidation of 4-iminoisatins, (v) the three-component catalytic condensation of 2-haloanilines with CO_2 and isocyanides (Scheme 1) [49,50]. Instead of phosgene, various phosgene surrogates can be used as a carbonylating agent, including phenylisocyanate [51] or Troc-group [52]. Recently, an alternative route for the synthesis of quinazoline-2,4-diones has been proposed, which consists of benzannulation strategy—the heteroaromatic condensed system is created by closing not the hetero-, but the carbocycle (Scheme 1, route vi) [53]. All these methods have a number of disadvantages; for example, poorly available or highly toxic reagents, harsh reaction conditions, difficulty in purifying target products, and low yields. Despite this, the synthesis of 3-substituted quinazolin-2,4-diones is still attractive due to their potential therapeutic application. Therefore, the development of convenient methods for the synthesis of new quinazolin-2,4-dione derivatives is an important task for organic and medicinal chemistry.

Scheme 1. Methods for synthesis of substituted quinazolin-2,4-diones.

The access to 3-substituted thienopyrimidine-2,4-diones is another significant point that does not have a convenient and general synthetic solution. In the literature, only two methods for the preparation of these compounds are described. One of them is a nucleophilic attack of an aminothiophene derivative on an isocyanate in the presence of a catalytic amount of triethylamine in refluxing 1,4-dioxane followed by treatment of formed intermediates with NaOR in refluxing ROH [54–56]. The other is a reaction of aminothiophene carboxamides with 2,2,6-trimethyl-*4H*-1,3-dioxin-4-one in xylene followed by formed enamino amides' fragmentation and cyclization [57].

Another significant goal is the introduction of the pyridyl moiety into organic molecules. In addition to being important pharmacophore themselves, this heterocycle can improve pharmacokinetic properties such as aqueous solubility and permeability through biological membranes. Therefore, it is of considerable interest to find convenient access to quinazolin-2,4-diones substituted in position 3 with pyridyl moiety. Unfortunately, a general synthetic method for obtaining a wide range of substituted 3-(pyridin-2-yl)quinazolin-2,4-diones is unknown hitherto. One of the best synthetic approaches to these compounds is a copper-catalyzed domino C–C bond cleavage of 2,3-unsubstituted indole/indolines/oxindoles through oxidation followed by insertion of 2-aminopyridines [58]. However, this method utilizes pyridine-2-amines, which are characterized by insufficient diversity and a rather high cost of commercially available compounds.

At present, our research is focused on the development of simple methods for introducing pyridin-2-yl and quinolin-2-yl fragments into organic and organometallic compounds based on the use of masked isocyanates—*N,N*-dialkyl-*N′*-(pyridine-2-yl)ureas [59–64]. These compounds are easily synthesized from the corresponding pyridines [65–68]. In this paper, we report a simple one-step protocol for the synthesis of 3-pyridyl-substituted quinazoline- and thienopyrimidine-2,4-diones from anthranilic or 2-aminothiophene-3-carboxylic acid esters that uses this approach. Taking into account the wide range of commercially available

pyridines, the proposed method has potential in the design of pharmaceutically relevant fused heterocycles.

2. Results and Discussion

Recently, we described the reaction of *N*-pyridyl ureas with a broad spectrum of amines [59]. During this study, the reaction of 1,1-dimethyl-3-(4-methylpyridin-2-yl)urea (**1a**) with anthranilic acid ethyl ester **2a** was carried out and unexpectedly quinazoline-2,4-dione **3a** was identified as the main product (the isolated yield of 51%). The more detailed study showed that the initially formed ethyl 2-(3-(5-methylpyridin-2-yl)ureido)benzoate (**4a**) undergoes further cyclocondensation under the reaction conditions to afford quinazolin-2,4-dione **3a** (Scheme 2).

Scheme 2. Formation of 3-(4-methylpyridin-2-yl)quinazoline-2,4(1*H*,3*H*)-dione (**3a**).

Product **3a** was characterized by high-resolution mass spectrometry and ^{1}H and ^{13}C NMR spectroscopies. The structure of the compound was confirmed by single-crystal X-ray diffraction (XRD, Figure 1 and Table S1).

**Figure 1.** Molecular structure of quinazoline-2,4-dione **3a** (Olex2 view).

We investigated the influence of the reaction conditions on the yield of **3a** (Table 1). We have determined that increasing the reaction time and temperature does not affect the yield (Table 1, entries 1 and 2). We enlarged the excess of anthranilic acid ethyl ester **2a** step by step in the reaction mixture and found that 5 equiv. of the one affords a higher yield (Table 1, entries 3–5). Then, we carried out the reaction under solvent-free conditions and the desired product **3a** was obtained in a better yield (Table 1, entry 6). A further increase in the **2a** excess reduced the yield of the product (Table 1, entry 7), so for the further experiments we used a 5-fold excess. Finally, we tested whether anthranilic acid could be used instead of its ester and found that the desired quinazoline-2,4-dione **3a** was formed, albeit in a lower yield (Table 1, entry 8).

After finding the optimal reaction conditions, we determined the range of possible substrates that can participate in the process. First, we studied various substituted (pyridin-2-yl)ureas **1** and showed that the reaction proceeds in all cases, but the reaction yields vary. This indicates the sensitivity of the reaction to electronic effects of substituents in the pyridine ring (Scheme 3), but the nature of this influence is ambiguous. It can be said that electron-donating groups in positions 4 and 5 of the pyridine ring have a positive effect on the yields of quinazoline-2,4-diones **3**. The presence of two methyl groups at positions 3 and 5 of the pyridine ring (*ortho* and *para* with respect to the nitrogen atom of the ureide fragment entering into the cyclocondensation) provides the target product **3e** with the highest yield (86%). It should be noted that quinazoline-2,4-dione **3c** bearing 5-methylpyridyl moiety was obtained in a slightly lower yield (48%).

Table 1. Optimization of the reaction conditions.

Entry	Equiv. of 2a	Solvent	Temperature, °C	Time, h	Yield, %
1	1.2	DMF	120	24	52
2	1.2	DMF	140	24	50
3	1.5	DMF	120	20	58
4	2.0	DMF	120	20	62
5	5.0	DMF	120	20	63
6	5.0	neat	120	20	70
7	10.0	neat	120	20	59
8 *	1.5	DMF	120	20	46

* Anthranilic acid was used instead ester **2a**.

R^1:
H, **3b**, 57%   6-Ph, **3g**, 42%
5-Me, **3c**, 65%   6-COOMe, **3h**, 51%
6-Me, **3d**, 48%   4-COOMe, **3i**, 56%
3,5-(Me)$_2$, **3e**, 86%   6-CN, **3j**, 55%
4-OMe, **3f**, 79%   4-CN, **3k**, 30%

R^2:
H, **3l**, 60%
4-OMe, **3m**, 78%
6-Me, **3n**, 66%
7-Me, **3o**, 48%
6-OMe, **3p**, 58%

3q, 47%

Scheme 3. Synthesis of quinazolin-2,4-diones substituted in the pyridine moiety.

The presence of electron-withdrawing groups in the heterocyclic ring also decreased the yield of products **3**. Perhaps this is due to such substituents adversely affecting the cyclocondensation step. Particularly, in the case of the substrate containing a nitro-group at position 4 of the pyridine ring, the desired quinazoline-2,4-dione was formed in only 19% yield (according to ^{1}H NMR data for the reaction mixture), whereas the main product was the corresponding intermediate urea. Moreover, the presence of the electron-withdrawing cyano-group in position 5 (*para* with respect to the nitrogen atom of the ureide fragment) completely suppressed the cyclocondensation. In this case, urea **4b** was isolated in 40% yield as the main product. The prolonged heating of **4b** at 120 °C only led to its degradation to the 2-aminopyridine **5** and the starting anthranilic acid ethyl ester **2a** (Scheme 4).

Scheme 4. Formation and destruction of ethyl 2-(3-(5-cyanopyridin-2-yl)ureido)benzoate **4b** under the reaction conditions.

Substituents in position 6 of the starting *N*–pyridylureas **1** slightly reduced the yield of target quinazolin-2,4-diones **3** (Scheme 3). The reason for this is the steric hindrances, but their effect is not very significant. Therefore, using ureas bearing quinoline and isoquinoline moieties **1l–q** as starting compounds, we synthesized 6 corresponding quinazolin-2,4-diones (**3l–q**) in moderate to good yields (47–78%, Scheme 3).

Next, we checked the possibility of synthesizing quinazolin-2,4-diones bearing substituents in the quinazoline fragment via the developed procedure. For this goal, the scope of functionalized anthranilic esters was investigated. Reactions were carried out with 1.5 equiv. of esters **2b–j** in DMF at 120 °C. We found that neither electron-donating nor electron-withdrawing substituents prevented the reaction and the corresponding quinazolin-2,4-diones (**3r–x,z**) were successfully obtained in 47–89% yields (Scheme 5). In addition, this method allows us to obtain *N1*-alkylsubstituted quinazolin-2,4-diones, however, with less yield. Particularly, the reaction between urea **1a** and *N*-methyl anthranilic ester **2h** provided target product **3y** with 32% yield only. Presumably, such poor yield of **3y** is caused by instability of *N*-alkyl-*N*-aryl urea (the proposed intermediate) in the reaction conditions and its side transformation into 1,3-bis(4-methylpyridin-2-yl)urea, which was also detected in the reaction mixture. This process was described in our previous work [59].

Scheme 5. Investigation of the reactivity of various anthranilic esters.

To expand the reaction scope, we studied the reactivity 2-aminothiophene-3-carboxylates (products of the Gewald reaction) in this process. It turned out that when ethyl 2-amino-4,5,6,7-tetrahydrobenzo[*b*]thiophene-3-carboxylate (**6a**) was used as a starting amine, the reaction stopped at the stage of the urea **7a** formation and any traces of a desired thienopyrimidine-2,4-dione were not observed in the reaction mixture (Scheme 6).

Scheme 6. Coupling of ureas **1a** with 2-aminothiophene-3-carboxylates **6a**.

Then, the conditions search for the implementation of the cyclocondensation was performed. Since the occurrence of similar reactions under basic conditions is described in the literature [50,69], we tested several bases and *t*-BuONa gave the best results. Having chosen the conditions for the cyclocondensation of the intermediate urea **7**, we synthesized

thienopyrimidine-2,4-diones **8a–f** in the overall yield of 35–56% according to the two-stage one-pot procedure (Scheme 7).

Scheme 7. Two-stage one-pot synthesis of thienopyrimidine-2,4-diones **8a–f**.

Finally, to highlight the practicality of this method, the scale-up syntheses of quinazoline-2,4-dione **3a** and thienopyrimidine-2,4-dione **8a** were performed (Scheme 8).

Scheme 8. Gram-scale syntheses of **3a** and **8a**. To achieve these yields, a 100 mL flask has to be used.

3. Material and Methods

3.1. General

The starting *N*-oxides, used to obtain the *N*-piridyl ureas, were synthesized according to the literature procedures [65,70–72]. All other reagents and solvents were purchased and were used as is. Column chromatography was carried out with silica gel grade 60 (0.040–0.063 mm) 230–400. NMR spectra were recorded on Bruker Avance DPX 400 (400 MHz, 101 MHz, and 376 MHz for ^{1}H, ^{13}C, and ^{19}F, respectively) in DMSO–d_6 or CDCl$_3$. Chemical shifts are reported as parts per million (δ, ppm). The ^{1}H and ^{13}C spectra were calibrated using the residual signals of nondeuterated solvents as internal reference (2.50 ppm for residual ^{1}H and 39.50 ppm for ^{13}C in DMSO–d_6, 7.26 ppm for residual ^{1}H and 77.16 ppm for ^{13}C in CDCl$_3$). ^{19}F NMR spectra were referenced through the solvent lock (2H) signal according to IUPAC recommended secondary referencing method and the manufacturer's protocols and the chemical shifts are reported relative to CFCl$_3$ (δ 0.0 ppm). Multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad; coupling constants, *J*, are reported in Hertz (Hz). Melting points were determined in open capillary tubes on Electrothermal IA 9300 series digital melting point apparatus. High–resolution mass spectra (HRMS) were measured on Bruker Maxis HRMS–ESI–qTOF (ESI ionization).

Singe crystal for X-ray studying was obtained by slow evaporation of DMSO solution of quinazoline-2,4,-dione **3a** at RT in air. X-ray diffraction data were collected via Rigaku XtaLAB Synergy–S diffractometer using CuKα (λ = 0.154184 nm) radiation. The structure was solved with the ShelXT [73] structure solution program using intrinsic phasing and refined with the ShelXL [74] refinement program incorporated in the OLEX2 program

package [75] using least squares minimization. Empirical absorption correction was applied in the CrysAlisPro [76] program complex using spherical harmonics, implemented in SCALE3 ABSPACK scaling algorithm. Supplementary crystallographic data for this paper have been deposited at Cambridge Crystallographic Data Centre and can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif (CCDC number 2249286) (accessed on 28 March 2023).

3.2. Preparation of Starting Ureas **1a–r**

Ureas **1a–d,f,i–k,r** [65], **1e,g,m** [59], **1l,q** [61] were prepared according to the previously reported protocols. Ureas **1h,n–p** were synthesized and characterized for the first time.

Synthesis of methyl 6-(3,3-dimethylureido)picolinate 1h. A mixture of *N*-oxide (1 mmol), dimethylcyanamide (1.5 mmol), and acetonitrile (2 mL, 20 mmol) was stirred at RT for 2 min, and then methanesulfonic acid (1.5 mmol) was added dropwise over 3 min. Then, the reaction mixture was gently heated to 60 °C and stirred for 3 h, cooled to RT, diluted with a saturated aq. Na_2CO_3 (2 mL) and aq. NaCl solution (5 mL) and extracted with ethyl acetate (4×15 mL). Combined organic fractions were dried over anhydrous Na_2SO_4, filtered, and concentrated in a rotary evaporator. The crude product was subjected to column chromatography on silica gel (EtOAc/hexane) to give target urea **1h** in 40% yield (90 mg) as a light-yellow powder; mp 74–75 °C. ^{1}H NMR (400 MHz, CDCl$_3$) δ 8.30 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.74–7.82 (m, 2H), 7.48 (s, 1H), 3.98 (s, 3H), 3.07 (s, 6H). ^{13}C NMR (101 MHz, CDCl$_3$) δ 165.5, 154.9, 153.2, 145.5, 139.0, 119.8, 117.3, 52.9, 36.6 (2C). HRMS (ESI), m/z: [M + Na]$^+$ calcd. for $C_{10}H_{13}N_3O_3$ 246.0849; found 246.0849.

Synthesis of ureas 1n–p. A mixture of substituted quinoline *N*-oxide (1 mmol), dimethylcyanamide (2 mmol), and acetonitrile (0.5 mL, 5 mmol) was stirred at RT for 2 min, and then methanesulfonic acid (1.1 mmol) was added dropwise over 3 min. Then, the reaction mixture was gently heated to 60 °C and stirred for 2 h, cooled, and diluted with a saturated aq. Na_2CO_3 (2 mL) and distilled water (5 mL). The precipitate formed was filtered off, washed with diethyl ether (10 mL) to give compounds **1n–p**.

1,1-Dimethyl-3-(6-methylquinolin-2-yl)urea 1n. Beige powder; 47 yield (108 mg); mp 140–141 °C. ^{1}H NMR (400 MHz, CDCl$_3$) δ 8.27 (d, *J* = 9.0 Hz, 1H), 8.03 (d, *J* = 9.0 Hz, 1H), 7.67 (d, *J* = 8.6 Hz, 1H), 7.53 (s, 1H), 7.47 (d, *J* = 8.6 Hz, 1H), 7.41 (s, 1H), 3.11 (s, 6H), 2.51 (s, 3H). ^{13}C NMR (101 MHz, CDCl$_3$) δ 155.1, 152.0, 145.2, 137.6, 134.2, 132.0, 126.7 (2C), 125.9, 114.2, 36.6 (2C), 21.4. HRMS (ESI), m/z: [M + H]$^+$ calcd. for $C_{13}H_{15}N_3O$ 230.1287; found 230.1290.

1,1-Dimethyl-3-(7-methylquinolin-2-yl)urea 1o. Beige powder; 51% yield (117 mg); mp 101–103 °C. ^{1}H NMR (400 MHz, CDCl$_3$) δ 8.23 (s, 1H), 8.05 (s, 1H), 7.80–7.42 (m, 3H), 7.22 (d, *J* = 8.2 Hz, 1H), 3.09 (s, 6H), 2.51 (s, 3H). ^{13}C NMR (101 MHz, CDCl$_3$) δ 155.1, 152.7, 147.0, 140.8, 140.2, 138.0, 127.3, 126.7, 126.1, 113.3, 36.6 (2C), 22.0. HRMS (ESI), m/z: [M + H]$^+$ calcd. for $C_{13}H_{15}N_3O$ 230.1288; found 230.1290.

3-(6-Methoxyquinolin-2-yl)-1,1-dimethylurea 1p. Beige powder; 99% yield (242 mg); mp 56–58 °C. ^{1}H NMR (400 MHz, CDCl$_3$) δ 8.27 (d, *J* = 9.0 Hz, 1H), 8.03 (d, *J* = 9.1 Hz, 1H), 7.69 (d, *J* = 9.2 Hz, 1H), 7.51 (br s, 1H), 7.30 (dd, *J* = 9.2, 2.9 Hz, 1H), 7.06 (d, *J* = 2.8 Hz, 1H), 3.92 (s, 3H), 3.11 (s, 6H). ^{13}C NMR (101 MHz, CDCl$_3$) δ 156.5, 155.3, 150.9, 142.3, 137.2, 128.2, 126.5, 122.1, 114.6, 105.8, 55.6, 36.6 (2C). HRMS (ESI), m/z: [M + H]$^+$ calcd. for $C_{13}H_{15}N_3O_2$ 246.1237; found 246.1226.

3.3. Synthesis of Quinazoline-2,4-Diones **3**

General procedure A. Urea **1** (0.2 mmol) and ethyl anthranilate **2** (1 mmol) were placed in a vial and the resulting mixture was stirred at 120 °C for 20 h. The reaction mixture was cooled to RT, treated with diethyl ether (5 mL), and the precipitate was separated, then the precipitate was washed with diethyl ether to give compounds **3a–q**.

General procedure B. Urea **1** (0.2 mmol), substituted ethyl anthranilate **2** (1 mmol), and DMF (0.1 mL) were placed in a vial and the resulting mixture was stirred at 120 °C for 20 h. The reaction mixture was cooled to RT, DMF was removed by a rotary evaporator, and the

residue was treated with diethyl ether (5 mL). The resulting precipitate was separated and washed with diethyl ether to give compounds **3r–z**.

3-(4-Methylpyridin-2-yl)quinazoline-2,4(1*H***,3***H***)-dione 3a** [58]. White powder; 70% yield (35 mg); mp 266–268 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.63 (s, 1H), 8.51–8.41 (m, 1H), 7.99–7.89 (m, 1H), 7.78–7.67 (m, 1H), 7.39–7.31 (m, 2H), 7.31–7.20 (m, 2H), 2.39 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.1, 149.9, 149.7, 149.2, 148.9, 139.9, 135.5, 127.5, 125.0, 124.8, 122.8, 115.4, 114.1, 20.3. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for $C_{14}H_{11}N_3O_2$ 276.0743; found 276.0750.

3-(Pyridin-2-yl)quinazoline-2,4(1*H***,3***H***)-dione 3b** [58]. White powder; 57% yield (27 mg); mp 266–267 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.63 (s, 1H), 8.63–8.58 (m, 1H), 8.00 (td, *J* = 7.7, 1.9 Hz, 1H), 7.95 (dd, *J* = 8.3, 1.6 Hz, 1H), 7.76–7.70 (m, 1H), 7.54–7.48 (m, 2H), 7.28–7.22 (m, 2H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.1, 149.9, 149.3, 149.3, 139.9, 138.7, 135.5, 127.5, 124.4, 124.1, 122.7, 115.4, 114.5. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for $C_{13}H_9N_3O_2$ 262.0587; found 262.0587.

3-(5-Methylpyridin-2-yl)quinazoline-2,4(1*H***,3***H***)-dione 3c** [58]. White powder; 65% yield (33 mg); mp 230–232 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.59 (s, 1H), 8.42 (d, *J* = 2.3 Hz, 1H), 7.97–7.91 (m, 1H), 7.80 (dd, *J* = 8.1, 2.4 Hz, 1H), 7.75–7.68 (m, 1H), 7.38 (d, *J* = 8.0 Hz, 1H), 7.27–7.20 (m, 2H), 2.38 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.1, 150.0, 149.3, 146.8, 139.9, 138.9, 135.4, 133.6, 127.5, 123.6, 122.7, 115.4, 114.2, 17.5. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for $C_{14}H_{11}N_3O_2$ 276.0743; found 276.0745.

3-(6-Methylpyridin-2-yl)quinazoline-2,4(1*H***,3***H***)-dione 3d** [58]. White powder; 48% yield (24 mg); mp 285–287 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.60 (s, 1H), 7.94 (dd, *J* = 8.3, 1.6 Hz, 1H), 7.87 (t, *J* = 7.7 Hz, 1H), 7.75–7.68 (m, 1H), 7.36 (d, *J* = 7.6 Hz, 1H), 7.29 (d, *J* = 7.8 Hz, 1H), 7.27–7.21 (m, 2H), 2.49 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.1, 158.1, 149.9, 148.5, 139.9, 138.8, 135.4, 127.4, 123.4, 122.7, 121.3, 115.4, 114.2, 23.6. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for $C_{14}H_{11}N_3O_2$ 276.0743; found 276.0747.

3-(3,5-Dimethylpyridin-2-yl)quinazoline-2,4(1*H***,3***H***)-dione 3e**. White powder; 86% yield (46 mg); mp 261–263 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.66 (s, 1H), 8.24 (d, *J* = 1.5 Hz, 1H), 7.96 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.77–7.70 (m, 1H), 7.69–7.64 (m, 1H), 7.31–7.23 (m, 2H), 2.35 (s, 3H), 2.08 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 161.7, 149.4, 147.0, 145.8, 140.0 (2C), 135.6, 133.9, 131.0, 127.5, 122.9, 115.5, 113.9, 17.3, 16.2. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for $C_{15}H_{13}N_3O_2$ 290.0900; found 290.0905.

3-(4-Methoxypyridin-2-yl)quinazoline-2,4(1*H***,3***H***)-dione 3f**. White powder; 79% yield (42 mg); mp 240–242 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.60 (s, 1H), 8.40 (d, *J* = 5.8 Hz, 1H), 7.94 (dd, *J* = 8.1, 1.6 Hz, 1H), 7.76–7.69 (m, 1H), 7.28–7.22 (m, 2H), 7.15 (d, *J* = 2.4 Hz, 1H), 7.09 (dd, *J* = 5.8, 2.5 Hz, 1H), 3.86 (s, 3H). ^{13}C NMR (101 MHz, DMSO) δ 167.1, 162.0, 150.8, 150.1, 149.8, 139.9, 135.5, 127.5, 122.7, 115.4, 114.2, 110.5, 110.4, 55.8. HRMS (ESI), m/z: [M + H]$^+$ calcd. for $C_{14}H_{11}N_3O_3$ 270.0873; found 270.0877.

3-(6-Phenylpyridin-2-yl)quinazoline-2,4(1*H***,3***H***)-dione 3g**. White powder; 42% yield (26 mg); mp 279–280 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.66 (s, 1H), 8.13–8.01 (m, 4H), 7.97 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.78–7.71 (m, 1H), 7.54–7.44 (m, 4H), 7.31–7.23 (m, 2H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.1, 156.3, 149.9, 149.2, 140.0, 139.8, 137.7, 135.5, 129.4, 128.8, 127.5, 126.7, 123.0, 122.8, 120.4, 115.5, 114.2. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for $C_{19}H_{13}N_3O_2$ 338.0900; found 338.0902.

Methyl 6-(2,4-dioxo-1,4-dihydroquinazolin-3(2*H***)-yl)picolinate 3h**. Light beige powder; 51% yield (30 mg); mp 247–249 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.72 (s, 1H), 8.26–8.16 (m, 2H), 7.99–7.93 (m, 1H), 7.82 (dd, *J* = 7.5, 1.3 Hz, 1H), 7.78–7.72 (m, 1H), 7.32–7.24 (m, 2H), 3.90 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 164.5, 162.1, 149.8, 149.3, 147.3, 140.3, 140.0, 135.6, 128.4, 127.5, 125.2, 122.9, 115.5, 114.1, 52.6. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for $C_{15}H_{11}N_3O_4$ 320.0642; found 320.0638.

Methyl 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2*H***)-yl)isonicotinate 3i**. Beige powder; 56% yield (33 mg); mp 233–235 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.67 (s, 1H), 8.83 (dd, *J* = 5.0, 0.8 Hz, 1H), 8.10–8.01 (m, 1H), 7.99–7.92 (m, 2H), 7.77–7.70 (m, 1H), 7.29–7.23 (m, 2H), 3.93 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 164.5, 162.2, 150.6, 150.5, 149.9, 140.0,

139.5, 135.5, 127.5, 123.7, 123.0, 122.8, 115.5, 114.2, 53.0. HRMS (ESI), m/z: [M + H]$^+$ calcd. for C$_{15}$H$_{11}$N$_3$O$_4$ 298.0822; found 298.0836.

6-(2,4-Dioxo-1,4-dihydroquinazolin-3(2*H*)-yl)picolinonitrile 3j. Light beige powder; 55% yield (29 mg); mp 295–297 °C (dec.). ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.72 (s, 1H), 8.31 (t, *J* = 7.8 Hz, 1H), 8.20 (d, *J* = 7.6 Hz, 1H), 8.01–7.90 (m, 2H), 7.79–7.72 (m, 1H), 7.32–7.22 (m, 2H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.0, 150.4, 149.6, 141.0, 140.0, 135.7, 132.0, 129.6, 129.4, 127.5, 122.9, 116.7, 115.6, 114.0. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for C$_{14}$H$_8$N$_4$O$_2$ 287.0539; found 287.0541.

2-(2,4-Dioxo-1,4-dihydroquinazolin-3(2*H*)-yl)isonicotinonitrile 3k. White powder; 30% yield (16 mg); mp 306–308 °C (dec.). ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.77 (s, 1H), 8.90 (d, *J* = 5.1 Hz, 1H), 8.16–8.09 (m, 1H), 8.03 (dd, *J* = 5.0, 1.5 Hz, 1H), 7.96 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.79–7.73 (m, 1H), 7.31–7.24 (m, 2H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.0, 151.0, 150.2, 149.6, 139.9, 135.8, 127.5, 126.7, 126.2, 123.0, 121.6, 116.1, 115.6, 114.0. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for C$_{14}$H$_8$N$_4$O$_2$ 287.0539; found 287.0536.

3-(Quinolin-2-yl)quinazoline-2,4(1*H*,3*H*)-dione 3l. White powder; 60% yield (35 mg); mp 256–259 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.71 (s, 1H), 8.57 (d, *J* = 8.5 Hz, 1H), 8.11 (d, *J* = 8.1 Hz, 1H), 8.03 (d, *J* = 8.4 Hz, 1H), 7.98 (d, *J* = 8.0 Hz, 1H), 7.87–7.82 (m, 1H), 7.78–7.70 (m, 2H), 7.66 (d, *J* = 8.5 Hz, 1H), 7.32–7.25 (m, 2H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.3, 150.0, 149.0, 146.9, 140.0, 138.8, 135.5, 130.1, 128.6, 127.9, 127.6, 127.5 (2C), 122.8, 122.1, 115.5, 114.3. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for C$_{17}$H$_{11}$N$_3$O$_2$ 312.0743; found 312.0747.

3-(4-Methoxyquinolin-2-yl)quinazoline-2,4(1*H*,3*H*)-dione 3m. White powder; 78% yield (50 mg); mp 284–285 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.69 (s, 1H), 8.21 (dd, *J* = 8.5, 1.5 Hz, 1H), 8.00–7.93 (m, 2H), 7.85–7.79 (m, 1H), 7.78–7.72 (m, 1H), 7.70–7.64 (m, 1H), 7.33–7.22 (m, 3H), 4.05 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 163.5, 162.1, 150.4, 149.9, 147.4, 140.0, 135.5, 130.4, 128.4, 127.4, 126.6, 122.8, 121.6, 120.4, 115.5, 114.2, 101.7, 56.6. HRMS (ESI), m/z: [M + H]$^+$ calcd. for C$_{18}$H$_{13}$N$_3$O$_3$ 320.1030; found 320.1033.

3-(6-Methylquinolin-2-yl)quinazoline-2,4(1*H*,3*H*)-dione 3n. White powder; 66% yield (40 mg); mp 310–311 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.69 (s, 1H), 8.45 (d, *J* = 8.5 Hz, 1H), 8.09–7.88 (m, 2H), 7.87 (s, 1H), 7.74 (t, *J* = 7.8 Hz, 1H), 7.68 (d, *J* = 8.6 Hz, 1H), 7.59 (d, *J* = 8.5 Hz, 1H), 7.40–7.14 (m, 2H), 2.56 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.3, 150.0, 148.2, 145.5, 140.0, 138.0, 137.0, 135.5, 132.2, 128.3, 127.7, 127.5, 126.6, 122.8, 122.1, 115.5, 114.3, 21.2. HRMS (ESI), m/z: [M + H]$^+$ calcd. for C$_{18}$H$_{13}$N$_3$O$_2$ 304.1081; found 304.1089.

3-(7-Methylquinolin-2-yl)quinazoline-2,4(1*H*,3*H*)-dione 3o. White powder; 48% yield (29 mg); mp 279–281 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.68 (s, 1H), 8.49 (d, *J* = 8.5 Hz, 1H), 7.98 (t, *J* = 8.5 Hz, 2H), 7.81 (s, 1H), 7.78–7.71 (m, 1H), 7.56 (d, *J* = 8.4 Hz, 2H), 7.34–7.22 (m, 2H), 2.56 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.3, 150.0, 149.0, 147.2, 140.1, 140.0, 138.4, 135.5, 129.6, 127.6, 127.5, 127.4, 125.7, 122.8, 121.2, 115.5, 114.3, 21.4. HRMS (ESI), m/z: [M + H]$^+$ calcd. for C$_{18}$H$_{13}$N$_3$O$_2$ 304.1081; found 304.1078.

3-(6-Methoxyquinolin-2-yl)quinazoline-2,4(1*H*,3*H*)-dione 3p. White powder; 58% yield (37 mg); mp 303–305 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.68 (s, 1H), 8.43 (d, *J* = 8.5 Hz, 1H), 7.97 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.92 (d, *J* = 8.9 Hz, 1H), 7.79–7.71 (m, 1H), 7.58 (d, *J* = 8.5 Hz, 1H), 7.53–7.44 (m, 2H), 7.32–7.22 (m, 2H), 3.94 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.3, 157.9, 150.1, 146.7, 142.8, 140.0, 137.5, 135.5, 130.0, 128.9, 127.5, 122.7, 122.5, 122.3, 115.5, 114.3, 105.8, 55.6. HRMS (ESI), m/z: [M + H]$^+$ calcd. for C$_{18}$H$_{13}$N$_3$O$_3$ 320.1030; found 320.1029.

3-(Isoquinolin-1-yl)quinazoline-2,4(1*H*,3*H*)-dione 3q. Light beige powder; 47% yield (27 mg); mp 269–271 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.80 (s, 1H), 8.53 (d, *J* = 5.6 Hz, 1H), 8.12 (d, *J* = 8.3 Hz, 1H), 8.03 (s, 1H), 8.02–7.99 (m, 1H), 7.97 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.88–7.83 (m, 1H), 7.81–7.75 (m, 1H), 7.69–7.64 (m, 1H), 7.35–7.27 (m, 2H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.4, 149.9, 148.6, 141.6, 140.3, 137.4, 135.7, 131.0, 128.7, 127.5, 127.0, 125.7, 124.5, 122.9, 122.3, 115.7, 114.1. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for C$_{17}$H$_{11}$N$_3$O$_2$ 312.0743; found 312.0746.

6-Methyl-3-(4-methylpyridin-2-yl)quinazoline-2,4(1*H*,3*H*)-dione 3r. White powder; 77% yield (41 mg); mp 304–305 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.53 (s, 1H), 8.44 (dd, *J* = 4.9, 0.8 Hz, 1H), 7.79–7.70 (m, 1H), 7.55 (dd, *J* = 8.4, 2.1 Hz, 1H), 7.37–7.28 (m, 2H), 7.16 (d, *J* = 8.2 Hz, 1H), 2.39 (s, 3H), 2.35 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.4, 149.8, 149.6, 149.3, 148.9, 137.7, 136.5, 132.0, 126.8, 124.9, 124.8, 115.4, 113.9, 20.3, 20.2. HRMS (ESI), m/z: [M + H]$^+$ calcd. for $C_{15}H_{13}N_3O_2$ 268.1081; found 268.1082.

8-Methyl-3-(4-methylpyridin-2-yl)quinazoline-2,4(1*H*,3*H*)-dione 3s. White powder; 74% yield (40 mg); mp 268–270 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 10.85 (s, 1H), 8.51–8.41 (m, 1H), 7.82 (dd, *J* = 7.8, 0.8 Hz, 1H), 7.57 (d, *J* = 7.3 Hz, 1H), 7.40–7.29 (m, 2H), 7.16 (t, *J* = 7.6 Hz, 1H), 2.41 (s, 3H), 2.40 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.2, 150.1, 149.7, 149.3, 148.9, 138.3, 136.5, 125.3, 125.0, 124.7, 124.3, 122.5, 114.3, 20.3, 17.2. HRMS (ESI), m/z: [M + H]$^+$ calcd. for $C_{15}H_{13}N_3O_2$ 268.1081; found 268.1083.

1-Methyl-3-(4-methylpyridin-2-yl)quinazoline-2,4(1*H*,3*H*)-dione 3t. White powder; 32% yield (17 mg); mp 224–225 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.45 (d, *J* = 5.1 Hz, 1H), 8.06 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.89–7.82 (m, 1H), 7.54 (d, *J* = 8.4 Hz, 1H), 7.39–7.30 (m, 3H), 3.54 (s, 3H), 2.40 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 161.2, 150.1, 149.7, 149.6, 148.9, 140.8, 135.8, 127.8, 125.0, 124.6, 122.9, 115.2, 114.9, 30.4, 20.3. HRMS (ESI), m/z: [M + H]$^+$ calcd. for $C_{15}H_{13}N_3O_2$ 268.1081; found 268.1087.

6,7-Dimethoxy-3-(4-methoxypyridin-2-yl)quinazoline-2,4(1*H*,3*H*)-dione 3u. White powder; 74% yield (49 mg); mp 238–240 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.39 (s, 1H), 8.39 (d, *J* = 5.7 Hz, 1H), 7.28 (s, 1H), 7.14–7.05 (m, 2H), 6.74 (s, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.80 (s, 3H). ^{13}C NMR (126 MHz, DMSO) δ 167.1, 161.5, 155.3, 151.0, 150.1, 149.9, 145.3, 135.7, 110.4 (2C), 107.5, 106.0, 97.7, 55.9, 55.8 (2C). HRMS (ESI), m/z: [M + H]$^+$ calcd. for $C_{16}H_{15}N_3O_5$ 330.1084; found 330.1090.

6-Fluoro-3-(4-methylpyridin-2-yl)quinazoline-2,4(1*H*,3*H*)-dione 3v. White powder; 89% yield (48 mg); mp 293–294 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.70 (s, 1H), 8.49–8.41 (m, 1H), 7.70–7.59 (m, 2H), 7.34 (d, *J* = 3.9 Hz, 2H), 7.32–7.26 (m, 1H), 2.39 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 161.8 (d, *J* = 3.1 Hz), 157.9 (d, *J* = 240.4 Hz), 150.2, 150.1, 149.5, 149.4, 137.1 (d, *J* = 1.3 Hz), 125.5, 125.2, 124.0 (d, *J* = 24.4 Hz), 118.3 (d, *J* = 7.9 Hz), 115.7 (d, *J* = 8.0 Hz), 112.9 (d, *J* = 24.0 Hz), 20.8. ^{19}F NMR (376 MHz, DMSO-d_6) δ –119.63. HRMS (ESI), m/z: [M + H]$^+$ calcd. for $C_{14}H_{10}FN_3O_2$ 272.0830; found 272.0829.

6-Chloro-3-(4-methylpyridin-2-yl)quinazoline-2,4(1*H*,3*H*)-dione 3w. White powder; 66% yield (38 mg); mp 301–302 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.77 (s, 1H), 8.45 (dd, *J* = 4.8, 1.0 Hz, 1H), 7.87 (d, *J* = 2.5 Hz, 1H), 7.78 (dd, *J* = 8.7, 2.5 Hz, 1H), 7.37–7.31 (m, 2H), 7.27 (d, *J* = 8.7 Hz, 1H), 2.39 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 161.1, 149.7, 149.6, 149.0, 148.9, 138.8, 135.4, 126.7, 126.3, 125.1, 124.7, 117.7, 115.6, 20.3. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for $C_{14}H_{10}ClN_3O_2$ 310.0354; found 310.0356.

7-Chloro-3-(4-methylpyridin-2-yl)quinazoline-2,4(1*H*,3*H*)-dione 3x. White powder; 47% yield (27 mg); mp 254–255 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.74 (s, 1H), 8.54–8.38 (m, 1H), 7.94 (d, *J* = 8.4 Hz, 1H), 7.38–7.31 (m, 2H), 7.29 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.26 (d, *J* = 1.9 Hz, 1H), 2.39 (s, 3H). ^{13}C NMR (126 MHz, DMSO-d_6) δ 161.4, 149.8, 149.7, 148.9, 141.0, 139.8, 129.6, 125.1, 124.7, 123.0, 114.8, 113.2, 20.3. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for $C_{14}H_{10}ClN_3O_2$ 310.0354; found 310.0351.

6-Bromo-3-(4-methylpyridin-2-yl)quinazoline-2,4(1*H*,3*H*)-dione 3y. Light beige powder; 62% yield (41 mg); mp 293–295 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.77 (s, 1H), 8.45 (dd, *J* = 4.9, 0.9 Hz, 1H), 8.00 (d, *J* = 2.3 Hz, 1H), 7.89 (dd, *J* = 8.7, 2.3 Hz, 1H), 7.38–7.31 (m, 2H), 7.21 (d, *J* = 8.7 Hz, 1H), 2.39 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 160.5, 149.2, 149.1, 148.5 (2C), 138.7, 137.5, 128.8, 124.6, 124.2, 117.4, 115.5, 113.7, 19.8. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for $C_{14}H_{10}BrN_3O_2$ 353.9849; found 353.9843.

Methyl 3-(4-methylpyridin-2-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline- 7-carboxylate 3z. White powder; 65% yield (41 mg); mp 266–267 °C (dec.). ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.82 (s, 1H), 8.45 (d, *J* = 5.4 Hz, 1H), 8.07 (d, *J* = 8.2 Hz, 1H), 7.83 (d, *J* = 1.5 Hz, 1H), 7.75 (dd, *J* = 8.2, 1.6 Hz, 1H), 7.39–7.30 (m, 2H), 3.92 (s, 3H), 2.40 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 165.1, 161.5, 149.8, 149.8, 149.0 (2C), 140.0, 135.3, 128.2, 125.1, 124.7, 122.5,

117.4, 116.3, 52.8, 20.3. HRMS (ESI), m/z: [M + H]+ calcd. for $C_{16}H_{13}BrN_3O_4$ 312.0979; found 312.0972.

Ethyl 2-(3-(5-cyanopyridin-2-yl)ureido)benzoate 4b. Compound **4b** was obtained according to the *general procedure A* from urea **1r** (0.15 mmol) and ethyl anthranilate (0.75 mmol). Beige powder; 40% yield (19 mg); mp 193–195 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 11.11 (s, 1H), 10.69 (s, 1H), 8.73 (d, *J* = 2.3 Hz, 1H), 8.29–8.22 (m, 1H), 8.17 (dd, *J* = 8.8, 2.3 Hz, 1H), 7.93 (dd, *J* = 7.9, 1.7 Hz, 1H), 7.68 (d, *J* = 8.8 Hz, 1H), 7.63–7.55 (m, 1H), 7.20–7.13 (m, 1H), 4.35 (q, *J* = 7.1 Hz, 2H), 1.33 (t, *J* = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 166.4, 155.2, 151.8, 151.6, 141.5, 139.6, 133.5, 130.5, 122.6, 121.9, 118.1, 117.4, 111.8, 101.7, 61.0, 14.0. HRMS (ESI), m/z: [M + H]+ calcd. for $C_{16}H_{14}N_4O_3$ 311.1139; found 311.1149.

3.4. Synthesis of Thienopyrimidine-2,4-Diones **8**

General procedure C. Urea **1** (0.2 mmol), amino ester **6** (0.3 mmol), and DMF (0.1 mL) were placed in a vial; the resulting mixture was stirred at 120 °C for 20 h. Then, the reaction mixture was cooled to RT and sodium *tert*-butoxide (0.2 mmol) and DMF (0.6 mL) were added. The reaction mixture was stirred for another 2 h at 120 °C. After completion of the reaction, the reaction mixture was cooled to RT, and DMF was removed by a rotary evaporator. The residue was purified by column chromatography (gradient from *n*–hexane/ethyl acetate to hexane/ethyl acetate/methanol) to give compounds **8a–f**.

3-(4-Methylpyridin-2-yl)-5,6,7,8-tetrahydrobenzo [4,5]thieno [2,3-*d*]pyrimidine-2,4 (1*H*,3*H*)-dione 8a. White powder; 54% yield (34 mg); mp 281–282 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 12.24 (br s, 1H), 8.41 (d, *J* = 5.0 Hz, 1H), 7.29 (d, *J* = 5.0 Hz, 1H), 7.23 (s, 1H), 2.67 (dt, *J* = 29.1, 6.4 Hz, 4H), 2.37 (s, 3H), 1.82–1.65 (m, 4H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 158.8, 150.5, 150.2, 149.5, 149.5, 148.9, 131.0, 125.7, 124.9, 124.8, 112.4, 24.9, 23.9, 22.7, 21.6, 20.3. HRMS (ESI), m/z: [M + H]+ calcd. for $C_{16}H_{15}N_3O_2S$ 314.0958; found 314.0960.

3-(Pyridin-2-yl)-5,6,7,8-tetrahydrobenzo [4,5]thieno [2,3-*d*]pyrimidine-2,4(1*H*,3*H*)-dione 8b. White powder; 50% yield (30 mg); mp 276–278 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 12.26 (s, 1H), 8.58 (dd, *J* = 5.0, 1.9 Hz, 1H), 7.97 (td, *J* = 7.7, 2.0 Hz, 1H), 7.51–7.41 (m, 2H), 2.76–2.61 (m, 4H), 1.83–1.67 (m, 4H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 158.7, 150.1 (2C), 149.4, 149.3, 138.6, 131.1, 125.9, 124.5, 123.9, 112.5, 24.9, 23.9, 22.7, 21.6. HRMS (ESI), m/z: [M + H]+ calcd. for $C_{15}H_{13}N_3O_2S$ 300.0801; found 300.0804.

3-(4-Methoxypyridin-2-yl)-5,6,7,8-tetrahydrobenzo [4,5]thieno [2,3-*d*]pyrimidine-2,4(1*H*,3*H*)-dione 8c. White powder; 45% yield (29 mg); mp 257–260 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 12.23 (s, 1H), 8.40–8.34 (m, 1H), 7.10–7.01 (m, 2H), 3.85 (s, 3H), 2.68 (dt, *J* = 29.4, 6.3 Hz, 4H), 1.83–1.66 (m, 4H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 167.0, 158.6, 150.9, 150.1, 150.1, 150.0, 131.0, 125.8, 112.5, 110.4, 110.3, 55.7, 24.9, 23.8, 22.7, 21.6. HRMS (ESI), m/z: [M + H]+ calcd. for $C_{16}H_{15}N_3O_3S$ 330.0907; found 330.0910.

3-(6-Phenylpyridin-2-yl)-5,6,7,8-tetrahydrobenzo [4,5]thieno [2,3-*d*]pyrimidine-2,4 (1*H*,3*H*)-dione 8d. Light yellow powder; 48% yield (36 mg); mp 293–294 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 12.30 (s, 1H), 8.13–7.93 (m, 4H), 7.56–7.38 (m, 4H), 2.70 (dt, *J* = 29.8, 6.3 Hz, 4H), 1.88–1.64 (m, 4H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 158.7, 156.3, 150.1, 150.1, 149.3, 139.7, 137.7, 131.0, 129.4, 128.8, 126.6, 125.9, 123.1, 120.2, 112.6, 24.9, 23.9, 22.7, 21.6. HRMS (ESI), m/z: [M + Na]+ calcd. for $C_{21}H_{17}N_3O_3S$ 398.0934; found 398.0939.

3-(Quinolin-2-yl)-5,6,7,8-tetrahydrobenzo [4,5]thieno [2,3-*d*]pyrimidine-2,4(1*H*,3*H*)-dione 8e. Light yellow powder; 56% yield (39 mg); mp 308–310 °C (dec.). ^{1}H NMR (400 MHz, DMSO-d_6) δ 12.35 (s, 1H), 8.53 (d, *J* = 8.5 Hz, 1H), 8.09 (dd, *J* = 8.4, 0.8 Hz, 1H), 8.01 (dd, *J* = 8.4, 1.0 Hz, 1H), 7.87–7.80 (m, 1H), 7.74–7.68 (m, 1H), 7.58 (d, *J* = 8.5 Hz, 1H), 2.70 (dt, *J* = 26.9, 6.3 Hz, 4H), 1.84–1.66 (m, 4H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 158.9, 150.3, 150.2, 149.2, 147.0, 138.7, 131.1, 130.0, 128.6, 127.9, 127.6, 127.4, 125.9, 122.3, 112.6, 24.9, 23.9, 22.7, 21.6. HRMS (ESI), m/z: [M + H]+ calcd. for $C_{19}H_{15}N_3O_3S$ 350.0958; found 350.0957.

3-(4-Methylpyridin-2-yl)-1,5,6,7-tetrahydro-2*H*-cyclopenta [4,5]thieno [2,3-*d*]pyrimidine-2,4(3*H*)-dione 8f. Brown powder; 35% yield (21 mg); mp 103–104 °C. ^{1}H NMR (400 MHz,

DMSO-d_6) δ 12.31 (s, 1H), 8.42 (d, J = 5.0 Hz, 1H), 7.31 (d, J = 5.2 Hz, 1H), 7.27 (s, 1H), 2.86–2.75 (m, 4H), 2.41–2.32 (m, 5H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 158.3, 154.6, 150.2, 149.6, 149.3, 148.9, 140.1, 130.7, 124.9, 109.8, 28.4, 28.3, 27.5, 20.3. HRMS (ESI), m/z: [M + Na]$^+$ calcd. for C$_{15}$H$_{13}$N$_3$O$_2$S 322.0621; found 322.0618.

Preparation of ethyl 2-(3-(4-methylpyridin-2-yl)ureido)-4,5,6,7-tetrahydrobenzo[b] thiophene-3-carboxylate 7a. Urea **1** (0.2 mmol), ethyl 2-amino-4,5,6,7-tetrahydrobenzo[*b*] thiophene-3-carboxylate **6a** (0.3 mmol) and DMF (0.1 mL) were placed in a vial, the resulting mixture was stirred at 120 °C for 20 h. After completion of the reaction, the reaction mixture was cooled to RT, DMF was removed by a rotary evaporator. The residue was washed with diethyl ether to give compound **7a** in 56% yield (40 mg) as a white powder; mp 237–238 °C. ^{1}H NMR (400 MHz, DMSO-d_6) δ 13.21 (br s, 1H), 10.27 (s, 1H), 8.17 (d, J = 5.2 Hz, 1H), 7.02 (s, 1H), 6.90 (dd, J = 5.2, 1.6 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 2.76–2.66 (m, 2H), 2.64–2.54 (m, 2H), 2.29 (s, 3H), 1.77–1.67 (m, 4H), 1.30 (t, J = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 164.2, 152.3, 151.5, 149.6, 147.4, 146.0, 130.4, 125.2, 119.1, 111.9, 110.6, 59.7, 26.0, 23.7, 22.5, 22.4, 20.8, 14.3. HRMS (ESI), m/z: [M + H]$^+$ calcd. for C$_{18}$H$_{21}$N$_3$O$_3$S 360.1376; found 360.1374.

3.5. Gram-Scale Synthesis of **3a** and **8a**

3a. Urea **1a** (5.6 mmol, 1 g) and ethyl anthranilate **2a** (27.9 mmol, 4.61 g) were placed in a 100 mL round-bottom flask and the resulting mixture was stirred at 120 °C for 20 h. The reaction mixture was cooled to RT, treated with diethyl ether (20 mL), and the precipitate was separated. Then, the precipitate was washed with diethyl ether and dried at 50 °C in air to give quinazoline-2,4-dione **3a** in 71% (1.01 g) yield.

8a. Urea **1a** (5.6 mmol, 1 g), ester **6a** (8.4 mmol, 1.89 g), and DMF (4 mL) were placed in a 100 mL round-bottom flask, the resulting mixture was stirred at 120 °C for 20 h. Then, the reaction mixture was cooled to RT and sodium *tert*-butoxide (5.6 mmol, 0.54 g) and DMF (17 mL) were added. The reaction mixture was stirred for another 2 h at 120 °C. After completion of the reaction, the reaction mixture was cooled to RT, and DMF was removed by a rotary evaporator. The residue was dissolved in isopropyl alcohol (150 mL) and the resultant solution was diluted with water (350 mL). The precipitate formed was filtered off and dried at 50 °C in air to give thienopyrimidine-2,4-dione **8a** in 61% (1.06 g) yield.

4. Conclusions

Thus, we developed a new route to 3-pyridyl-substituted quinazolin-2,4(1*H*,3*H*)-diones and thieno [2,3-*d*]pyrimidine-2,4(1*H*,3*H*)-diones via the annulation of anthranilic esters with *N*-pyridyl ureas, which act as masked isocyanates. The process consists of the formation of *N*-aryl-*N*′-pyridyl ureas followed by their cyclocondensation into the corresponding diones. The reaction does not require the use of metal catalysts and proceeds with moderate to good yields. The synthetic route we propose will successfully complement the method developed by Ravi et al. [58] for the preparation of quinazolin-2,4(1*H*,3*H*)-diones based on aminopyridines in cases where the corresponding aminopyridines or quinolines are not commercially available.

Although the nature of the substituent in the pyridine ring has little effect on the product yield, strong electron-withdrawing functionalities such as cyano-group decrease the yield of the desired products or even prevent the cyclocondensation step. The proposed method is characterized by uncomplicated workup and easy gram-scalability.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Faught, E. BGG492 (Selurampanel), an AMPA/Kainate Receptor Antagonist Drug for Epilepsy. *Expert Opin. Investig. Drugs* **2014**, *23*, 107–113. [CrossRef] [PubMed]

2. Orain, D.; Tasdelen, E.; Haessig, S.; Koller, M.; Picard, A.; Dubois, C.; Lingenhoehl, K.; Desrayaud, S.; Floersheim, P.; Carcache, D.; et al. Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist. *ChemMedChem* **2017**, *12*, 197–201. [CrossRef]

3. Ueno, M.; Rao, S.V.; Angiolillo, D.J. Elinogrel: Pharmacological Principles, Preclinical and Early Phase Clinical Testing. *Future Cardiol.* **2010**, *6*, 445–453. [CrossRef]

4. Welsh, R.C.; Rao, S.V.; Zeymer, U.; Thompson, V.P.; Huber, K.; Kochman, J.; McClure, M.W.; Gretler, D.D.; Bhatt, D.L.; Gibson, C.M.; et al. A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y 12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention. *Circ. Cardiovasc. Interv.* **2012**, *5*, 336–346. [CrossRef]

5. Siller-Matula, J.M.; Krumphuber, J.; Jilma, B. Pharmacokinetic, Pharmacodynamic and Clinical Profile of Novel Antiplatelet Drugs Targeting Vascular Diseases. *Br. J. Pharmacol.* **2010**, *159*, 502–517. [CrossRef] [PubMed]

6. Brown, M.J.; Bird, S.J.; Watling, S.; Kaleta, H.; Hayes, L.; Eckert, S.; Foyt, H.L. Natural Progression of Diabetic Peripheral Neuropathy in the Zenarestat Study Population. *Diabetes Care* **2004**, *27*, 1153–1159. [CrossRef]

7. Shimoshige, Y.; Minoura, K.; Matsuoka, N.; Takakura, S.; Mutoh, S.; Kamijo, M. Thirteen-Month Inhibition of Aldose Reductase by Zenarestat Prevents Morphological Abnormalities in the Dorsal Root Ganglia of Streptozotocin-Induced Diabetic Rats. *Brain Res.* **2009**, *1247*, 182–187. [CrossRef]

8. Vanhoutte, P.; Amery, A.; Birkenhäger, W.; Breckenridge, A.; Bühler, F.; Distler, A.; Dormandy, J.; Doyle, A.; Frohlich, E.; Hansson, L. Serotoninergic Mechanisms in Hypertension. Focus on the Effects of Ketanserin. *Hypertension* **1988**, *11*, 111–133. [CrossRef]

9. Liechti, M. Psychological and Physiological Effects of MDMA ("Ecstasy") after Pretreatment with the 5-HT2 Antagonist Ketanserin in Healthy Humans. *Neuropsychopharmacology* **2000**, *23*, 396–404. [CrossRef] [PubMed]

10. Dhillon, S. Carotegrast Methyl: First Approval. *Drugs* **2022**, *82*, 1011–1016. [CrossRef]

11. Sugiura, T.; Kageyama, S.; Andou, A.; Miyazawa, T.; Ejima, C.; Nakayama, A.; Dohi, T.; Eda, H. Oral Treatment with a Novel Small Molecule Alpha 4 Integrin Antagonist, AJM300, Prevents the Development of Experimental Colitis in Mice. *J. Crohn's Colitis* **2013**, *7*, e533–e542. [CrossRef]

12. Hu, X.; Zhang, J.; Zhang, Y.; Jiao, F.; Wang, J.; Chen, H.; Ouyang, L.; Wang, Y. Dual-Target Inhibitors of Poly (ADP-Ribose) Polymerase-1 for Cancer Therapy: Advances, Challenges, and Opportunities. *Eur. J. Med. Chem.* **2022**, *230*, 114094. [CrossRef]

13. Peng, X.; Pan, W.; Jiang, F.; Chen, W.; Qi, Z.; Peng, W.; Chen, J. Selective PARP1 Inhibitors, PARP1-Based Dual-Target Inhibitors, PROTAC PARP1 Degraders, and Prodrugs of PARP1 Inhibitors for Cancer Therapy. *Pharmacol. Res.* **2022**, *186*, 106529. [CrossRef]

14. Gao, B.; Voskoboynik, M.; Cooper, A.; Wilkinson, K.; Hoon, S.; Hsieh, C.; Cai, S.; Tian, Y.E.; Bao, J.; Ma, N.; et al. A Phase 1 Dose-escalation Study of the Poly(ADP-ribose) Polymerase Inhibitor Senaparib in Australian Patients with Advanced Solid Tumors. *Cancer* **2023**, *129*, 1041–1050. [CrossRef] [PubMed]

15. Gillooly, K.M.; Pulicicchio, C.; Pattoli, M.A.; Cheng, L.; Skala, S.; Heimrich, E.M.; McIntyre, K.W.; Taylor, T.L.; Kukral, D.W.; Dudhgaonkar, S.; et al. Bruton's Tyrosine Kinase Inhibitor BMS-986142 in Experimental Models of Rheumatoid Arthritis Enhances Efficacy of Agents Representing Clinical Standard-of-Care. *PLoS ONE* **2017**, *12*, e0181782. [CrossRef] [PubMed]

16. Watterson, S.H.; De Lucca, G.V.; Shi, Q.; Langevine, C.M.; Liu, Q.; Batt, D.G.; Beaudoin Bertrand, M.; Gong, H.; Dai, J.; Yip, S.; et al. Discovery of 6-Fluoro-5-(*R*)-(3-*S*)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4*H*)-yl)-2-methylphenyl)-2-(*S*)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1*H*-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine. *J. Med. Chem.* **2016**, *59*, 9173–9200. [CrossRef]

17. Lee, S.K.; Xing, J.; Catlett, I.M.; Adamczyk, R.; Griffies, A.; Liu, A.; Murthy, B.; Nowak, M. Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986142, a Novel Reversible BTK Inhibitor, in Healthy Participants. *Eur. J. Clin. Pharmacol.* **2017**, *73*, 689–698. [CrossRef] [PubMed]

18. Nencini, A.; Pratelli, C.; Quinn, J.M.; Salerno, M.; Tunici, P.; De Robertis, A.; Valensin, S.; Mennillo, F.; Rossi, M.; Bakker, A.; et al. Structure–Activity Relationship and Properties Optimization of a Series of Quinazoline-2,4-diones as Inhibitors of the Canonical Wnt Pathway. *Eur. J. Med. Chem.* **2015**, *95*, 526–545. [CrossRef]

19. Falsini, M.; Squarcialupi, L.; Catarzi, D.; Varano, F.; Betti, M.; Di Cesare Mannelli, L.; Tenci, B.; Ghelardini, C.; Tanc, M.; Angeli, A.; et al. 3-Hydroxy-1*H*-quinazoline-2,4-dione as a New Scaffold To Develop Potent and Selective Inhibitors of the Tumor-Associated Carbonic Anhydrases IX and XII. *J. Med. Chem.* **2017**, *60*, 6428–6439. [CrossRef]

20. Yu, C.-W.; Hung, P.-Y.; Yang, H.-T.; Ho, Y.-H.; Lai, H.-Y.; Cheng, Y.-S.; Chern, J.-W. Quinazolin-2,4-dione-based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer. *J. Med. Chem.* **2019**, *62*, 857–874. [CrossRef] [PubMed]

21. El-Adl, K.; El-Helby, A.A.; Sakr, H.; El-Hddad, S.S.A. Design, Synthesis, Molecular Docking, and Anticancer Evaluations of 1-benzylquinazoline-2,4(1*H*,3*H*)-dione Bearing Different Moieties as VEGFR-2 Inhibitors. *Arch. Pharm.* **2020**, *353*, 2000068. [CrossRef] [PubMed]

22. Qin, D.; Lin, X.; Liu, Z.; Chen, Y.; Zhang, Z.; Wu, C.; Liu, L.; Pan, Y.; Laquerre, S.; Emery, J.; et al. Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors. *ACS Med. Chem. Lett.* **2021**, *12*, 1005–1010. [CrossRef] [PubMed]

23. Kakuta, H.; Tanatani, A.; Nagasawa, K.; Hashimoto, Y. Specific Nonpeptide Inhibitors of Puromycin-Sensitive Aminopeptidase with a 2,4(1*H*,3*H*)-Quinazolinedione Skeleton. *Chem. Pharm. Bull.* **2003**, *51*, 1273–1282. [CrossRef] [PubMed]

24. Luo, Z.; Liu, H.; Yu, Y.; Gropler, R.J.; Klein, R.S.; Tu, Z. Synthesis and Evaluation of Highly Selective Quinazoline-2,4-dione Ligands for Sphingosine-1-phosphate Receptor 2. *RSC Med. Chem.* **2022**, *13*, 202–207. [CrossRef]

25. Gazzillo, E.; Terracciano, S.; Ruggiero, D.; Potenza, M.; Chini, M.G.; Lauro, G.; Fischer, K.; Hofstetter, R.K.; Giordano, A.; Werz, O.; et al. Repositioning of Quinazolinedione-Based Compounds on Soluble Epoxide Hydrolase (SEH) through 3D Structure-Based Pharmacophore Model-Driven Investigation. *Molecules* **2022**, *27*, 3866. [CrossRef]

26. Kirincich, S.J.; Xiang, J.; Green, N.; Tam, S.; Yang, H.Y.; Shim, J.; Shen, M.W.H.; Clark, J.D.; McKew, J.C. Benzhydrylquinazoline-diones: Novel Cytosolic Phospholipase A2α Inhibitors with Improved Physicochemical Properties. *Bioorg. Med. Chem.* **2009**, *17*, 4383–4405. [CrossRef]

27. Elansary, A.K.; Kadry, H.H.; Ahmed, E.M.; Sonousi, A.S.M. Design, Synthesis, and Biological Activity of Certain Quinazolinedione Derivatives as Potent Phosphodiestrase4 Inhibitors. *Med. Chem. Res.* **2012**, *21*, 3557–3567. [CrossRef]

28. Głowacka, I.E.; Gawron, K.; Piotrowska, D.G.; Graus, M.; Andrei, G.; Schols, D.; Snoeck, R.; Camps, A.; Vanhulle, E.; Vermeire, K. Design and Synthesis of a New Series of Hybrids of Functionalised N^1-[(1*H*-1,2,3-Triazol-4-yl)methyl]quinazoline-2,4-dione with Antiviral Activity against Respiratory Syncytial Virus. *Antivir. Res.* **2023**, *209*, 105518. [CrossRef]

29. Tatarinov, D.A.; Garifullin, B.F.; Belenok, M.G.; Andreeva, O.V.; Strobykina, I.Y.; Shepelina, A.V.; Zarubaev, V.V.; Slita, A.V.; Volobueva, A.S.; Saifina, L.F.; et al. The First 5′-Phosphorylated 1,2,3-Triazolyl Nucleoside Analogues with Uracil and Quinazoline-2,4-Dione Moieties: A Synthesis and Antiviral Evaluation. *Molecules* **2022**, *27*, 6214. [CrossRef]

30. Boshta, N.M.; El-Essawy, F.A.; Alshammari, M.B.; Noreldein, S.G.; Darwesh, O.M. Discovery of Quinazoline-2,4(1*H*,3*H*)-Dione Derivatives as Potential Antibacterial Agent: Design, Synthesis, and Their Antibacterial Activity. *Molecules* **2022**, *27*, 3853. [CrossRef]

31. Lansdon, E.B.; Liu, Q.; Leavitt, S.A.; Balakrishnan, M.; Perry, J.K.; Lancaster-Moyer, C.; Kutty, N.; Liu, X.; Squires, N.H.; Watkins, W.J.; et al. Structural and Binding Analysis of Pyrimidinol Carboxylic Acid and *N*-Hydroxy Quinazolinedione HIV-1 RNase H Inhibitors. *Antimicrob. Agents Chemother.* **2011**, *55*, 2905–2915. [CrossRef] [PubMed]

32. Malik, M.; Marks, K.R.; Mustaev, A.; Zhao, X.; Chavda, K.; Kerns, R.J.; Drlica, K. Fluoroquinolone and Quinazolinedione Activities against Wild-Type and Gyrase Mutant Strains of Mycobacterium Smegmatis. *Antimicrob. Agents Chemother.* **2011**, *55*, 2335–2343. [CrossRef] [PubMed]

33. Enciso, E.; Sarmiento-Sánchez, J.I.; López-Moreno, H.S.; Ochoa-Terán, A.; Osuna-Martínez, U.; Beltrán-López, E. Synthesis of New Quinazolin-2,4-diones as Anti-Leishmania Mexicana Agents. *Mol. Divers.* **2016**, *20*, 821–828. [CrossRef] [PubMed]

34. Mourot, L.; Schmitt, M.; Mouray, E.; Spichty, M.; Florent, I.; Albrecht, S. Structure-Activity Relationship and Molecular Modelling Studies of Quinazolinedione Derivatives MMV665916 as Potential Antimalarial Agent. *Bioorg. Med. Chem.* **2021**, *51*, 116513. [CrossRef]

35. Swann, J.; Corey, V.; Scherer, C.A.; Kato, N.; Comer, E.; Maetani, M.; Antonova-Koch, Y.; Reimer, C.; Gagaring, K.; Ibanez, M.; et al. High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria. *ACS Infect. Dis.* **2016**, *2*, 281–293. [CrossRef]

36. Ji, Q.; Yang, D.; Wang, X.; Chen, C.; Deng, Q.; Ge, Z.; Yuan, L.; Yang, X.; Liao, F. Design, Synthesis and Evaluation of Novel Quinazoline-2,4-dione Derivatives as Chitin Synthase Inhibitors and Antifungal Agents. *Bioorg. Med. Chem.* **2014**, *22*, 3405–3413. [CrossRef]

37. Ali, E.M.H.; Abdel-Maksoud, M.S.; Oh, C.-H. Thieno [2,3-*d*]pyrimidine as a Promising Scaffold in Medicinal Chemistry: Recent Advances. *Bioorg. Med. Chem.* **2019**, *27*, 1159–1194. [CrossRef]

38. Markham, A. Relugolix: First Global Approval. *Drugs* **2019**, *79*, 675–679. [CrossRef]

39. Nakata, D.; Masaki, T.; Tanaka, A.; Yoshimatsu, M.; Akinaga, Y.; Asada, M.; Sasada, R.; Takeyama, M.; Miwa, K.; Watanabe, T.; et al. Suppression of the Hypothalamic–Pituitary–Gonadal Axis by TAK-385 (Relugolix), a Novel, Investigational, Orally Active, Small Molecule Gonadotropin-Releasing Hormone (GnRH) Antagonist: Studies in Human GnRH Receptor Knock-in Mice. *Eur. J. Pharmacol.* **2014**, *723*, 167–174. [CrossRef]

40. Miwa, K.; Hitaka, T.; Imada, T.; Sasaki, S.; Yoshimatsu, M.; Kusaka, M.; Tanaka, A.; Nakata, D.; Furuya, S.; Endo, S.; et al. Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno [2,3-*d*]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonad. *J. Med. Chem.* **2011**, *54*, 4998–5012. [CrossRef]

41. Zou, F.; Wang, Y.; Yu, D.; Liu, C.; Lu, J.; Zhao, M.; Ma, M.; Wang, W.; Jiang, W.; Gao, Y.; et al. Discovery of the Thieno [2,3-*d*]pyrimidine-2,4-dione Derivative 21a: A Potent and Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist. *Eur. J. Med. Chem.* **2022**, *242*, 114679. [CrossRef] [PubMed]

42. Guo, Z.; Chen, Y.; Wu, D.; Zhu, Y.-F.; Struthers, R.S.; Saunders, J.; Xie, Q.; Chen, C. Synthesis and Structure–Activity Relationships of Thieno [2,3-*d*]pyrimidine-2,4-dione Derivatives as Potent GnRH Receptor Antagonists. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 3617–3622. [CrossRef] [PubMed]

43. Sasaki, S.; Cho, N.; Nara, Y.; Harada, M.; Endo, S.; Suzuki, N.; Furuya, S.; Fujino, M. Discovery of a Thieno [2,3-*d*]pyrimidine-2,4-dione Bearing a *p*-Methoxyureidophenyl Moiety at the 6-Position: A Highly Potent and Orally Bioavailable Non-Peptide Antagonist for the Human Luteinizing Hormone-Releasing Hormone Receptor. *J. Med. Chem.* **2003**, *46*, 113–124. [CrossRef] [PubMed]

44. Alkhouri, N.; Lawitz, E.; Noureddin, M.; DeFronzo, R.; Shulman, G.I. GS-0976 (Firsocostat): An Investigational Liver-Directed Acetyl-CoA Carboxylase (ACC) Inhibitor for the Treatment of Non-Alcoholic Steatohepatitis (NASH). *Expert Opin. Investig. Drugs* **2020**, *29*, 135–141. [CrossRef]

45. Loomba, R.; Noureddin, M.; Kowdley, K.V.; Kohli, A.; Sheikh, A.; Neff, G.; Bhandari, B.R.; Gunn, N.; Caldwell, S.H.; Goodman, Z.; et al. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. *Hepatology* **2021**, *73*, 625–643. [CrossRef]

46. Alkhouri, N.; Herring, R.; Kabler, H.; Kayali, Z.; Hassanein, T.; Kohli, A.; Huss, R.S.; Zhu, Y.; Billin, A.N.; Damgaard, L.H.; et al. Safety and Efficacy of Combination Therapy with Semaglutide, Cilofexor and Firsocostat in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Open-Label Phase II Trial. *J. Hepatol.* **2022**, *77*, 607–618. [CrossRef]

47. Wang, D.-W.; Lin, H.-Y.; Cao, R.-J.; Yang, S.-G.; Chen, Q.; Hao, G.-F.; Yang, W.-C.; Yang, G.-F. Synthesis and Herbicidal Evaluation of Triketone-Containing Quinazoline-2,4-diones. *J. Agric. Food Chem.* **2014**, *62*, 11786–11796. [CrossRef]

48. Wang, D.-W.; Zhang, H.; Yu, S.-Y.; Zhang, R.-B.; Liang, L.; Wang, X.; Yang, H.-Z.; Xi, Z. Discovery of a Potent Thieno [2,3-*d*]Pyrimidine-2,4-dione-Based Protoporphyrinogen IX Oxidase Inhibitor through an In Silico Structure-Guided Optimization Approach. *J. Agric. Food Chem.* **2021**, *69*, 14115–14125. [CrossRef]

49. Gheidari, D.; Mehrdad, M.; Maleki, S. The Quinazoline-2,4(1*H*,3*H*)-diones Skeleton: A Key Intermediate in Drug Synthesis. *Sustain. Chem. Pharm.* **2022**, *27*, 100696. [CrossRef]

50. Gheidari, D.; Mehrdad, M.; Maleki, S. Recent Advances in Synthesis of Quinazoline-2,4(1*H*,3*H*)-diones: Versatile Building Blocks in *N*-Heterocyclic Compounds. *Appl. Organomet. Chem.* **2022**, *36*, e6631. [CrossRef]

51. Govindan, K.; Jayaram, A.; Duraisamy, T.; Chen, N.-Q.; Lin, W.-Y. Metal-Free N–H/C–H Carbonylation by Phenyl Isocyanate: Divergent Synthesis of Six-Membered *N*-Heterocycles. *J. Org. Chem.* **2022**, *87*, 8719–8729. [CrossRef] [PubMed]

52. Dong, X.; Ma, P.; Zhang, T.; Jalani, H.B.; Li, G.; Lu, H. Iridium-Catalyzed C–H Amination of Weinreb Amides: A Facile Pathway toward Anilines and Quinazolin-2,4-diones. *J. Org. Chem.* **2020**, *85*, 13096–13107. [CrossRef] [PubMed]

53. Ghosh, A.; Shee, S.; Biju, A.T. A Benzannulation Strategy for Rapid Access to Quinazoline-2,4-diones via Oxidative *N*-Heterocyclic Carbene Catalysis. *Org. Lett.* **2022**, *24*, 2772–2777. [CrossRef] [PubMed]

54. Abu-Hashem, A.A.; Abu-Zied, K.M.; El-Shehry, M.F. Synthetic Utility of Bifunctional Thiophene Derivatives and Antimicrobial Evaluation of the Newly Synthesized Agents. *Monatsh. Chem.* **2011**, *142*, 539–545. [CrossRef]

55. Dewal, M.B.; Wani, A.S.; Vidaillac, C.; Oupický, D.; Rybak, M.J.; Firestine, S.M. Thieno [2,3-*d*]pyrimidinedione Derivatives as Antibacterial Agents. *Eur. J. Med. Chem.* **2012**, *51*, 145–153. [CrossRef] [PubMed]

56. Lagardère, P.; Fersing, C.; Masurier, N.; Lisowski, V. Thienopyrimidine: A Promising Scaffold to Access Anti-Infective Agents. *Pharmaceuticals* **2021**, *15*, 35. [CrossRef]

57. El-Meligie, S.E.M.; Khalil, N.A.; El-Nassan, H.B.; Ibraheem, A.A.M. New Synthetic Approaches to Thieno [3,2-*d*]pyrimidine and Thieno [3,4-*b*]pyridine Derivatives. *Chem. Pap.* **2020**, *74*, 2501–2514. [CrossRef]

58. Ravi, O.; Ramaraju, A.; Sridhar, B.; Bathula, S.R. Copper-Catalyzed Domino C−C Bond Cleavage of 2,3-Unsubstituted Indoles/Indolines and Oxindoles via Oxidation and Directed Insertion of 2-Aminopyridines: Direct Access to Quinazolinediones. *Adv. Synth. Catal.* **2018**, *360*, 3009–3014. [CrossRef]

59. Kasatkina, S.O.; Geyl, K.K.; Baykov, S.V.; Novikov, M.S.; Boyarskiy, V.P. "Urea to Urea" Approach: Access to Unsymmetrical Ureas Bearing Pyridyl Substituents. *Adv. Synth. Catal.* **2022**, *364*, 1295–1304. [CrossRef]

60. Kasatkina, S.O.; Geyl, K.K.; Baykov, S.V.; Boyarskaya, I.A.; Boyarskiy, V.P. Catalyst-Free Synthesis of Substituted Pyridin-2-yl, Quinolin-2-yl, and Isoquinolin-1-yl Carbamates from the Corresponding Hetaryl Ureas and Alcohols. *Org. Biomol. Chem.* **2021**, *19*, 6059–6065. [CrossRef]

61. Dobrynin, M.V.; Kasatkina, S.O.; Baykov, S.V.; Savko, P.Y.; Antonov, N.S.; Mikherdov, A.S.; Boyarskiy, V.P.; Islamova, R.M. Deprotonated Diaminocarbene Platinum Complexes for Thermoresponsive Luminescent Silicone Materials: Both Catalysts and Luminophores. *Dalt. Trans.* **2021**, *50*, 14994–14999. [CrossRef] [PubMed]

62. Geyl, K.K.; Baykov, S.V.; Kasatkina, S.O.; Savko, P.Y.; Boyarskiy, V.P. Reaction of Coordinated Isocyanides with Substituted *N*-(2-Pyridyl) Ureas as a Route to New Cyclometallated Pd(II) Complexes. *J. Organomet. Chem.* **2022**, *980–981*, 122518. [CrossRef]

63. Geyl, K.K.; Baykov, S.V.; Kalinin, S.A.; Bunev, A.S.; Troshina, M.A.; Sharonova, T.V.; Skripkin, M.Y.; Kasatkina, S.O.; Presnukhina, S.I.; Shetnev, A.A.; et al. Synthesis, Structure, and Antiproliferative Action of 2-Pyridyl Urea-Based Cu(II) Complexes. *Biomedicines* **2022**, *10*, 461. [CrossRef]

64. Geyl, K.K.; Baykova, S.O.; Andoskin, P.A.; Sharoyko, V.V.; Eliseeva, A.A.; Baykov, S.V.; Semenov, K.N.; Boyarskiy, V.P. Palladium(II) and Platinum(II) Deprotonated Diaminocarbene Complexes Based on *N*-(2-Pyridyl)Ureas with Oxadiazole Periphery. *Inorganics* **2022**, *10*, 247. [CrossRef]

65. Rassadin, V.A.; Zimin, D.P.; Raskil'dina, G.Z.; Ivanov, A.Y.; Boyarskiy, V.P.; Zlotskii, S.S.; Kukushkin, V.Y. Solvent- and Halide-Free Synthesis of Pyridine-2-yl Substituted Ureas through Facile C–H Functionalization of Pyridine *N*-Oxides. *Green Chem.* **2016**, *18*, 6630–6636. [CrossRef]

66. Geyl, K.; Baykov, S.; Tarasenko, M.; Zelenkov, L.E.; Matveevskaya, V.; Boyarskiy, V.P. Convenient Entry to *N*-Pyridinylureas with Pharmaceutically Privileged Oxadiazole Substituents via the Acid-Catalyzed C–H Activation of *N*-Oxides. *Tetrahedron Lett.* **2019**, *60*, 151108. [CrossRef]

67. Baykov, S.; Mikherdov, A.; Novikov, A.; Geyl, K.; Tarasenko, M.; Gureev, M.; Boyarskiy, V. π–π Noncovalent Interaction Involving 1,2,4- and 1,3,4-Oxadiazole Systems: The Combined Experimental, Theoretical, and Database Study. *Molecules* **2021**, *26*, 5672. [CrossRef]

68. Baykov, S.V.; Boyarskiy, V.P. Metal-Free Functionalization of Azine *N*-Oxides with Electrophilic Reagents. *Chem. Heterocycl. Compd.* **2020**, *56*, 814–823. [CrossRef]

69. Tian, X.-C.; Huang, X.; Wang, D.; Gao, F. Eco-Efficient One-Pot Synthesis of Quinazoline-2,4(1*H*,3*H*)-Diones at Room Temperature in Water. *Chem. Pharm. Bull.* **2014**, *62*, 824–829. [CrossRef]

70. Inamoto, K.; Araki, Y.; Kikkawa, S.; Yonemoto, M.; Tanaka, Y.; Kondo, Y. Organocatalytic Functionalization of Heteroaromatic *N*-Oxides with C-Nucleophiles Using in Situ Generated Onium Amide Bases. *Org. Biomol. Chem.* **2013**, *11*, 4438. [CrossRef]

71. Wengryniuk, S.E.; Weickgenannt, A.; Reiher, C.; Strotman, N.A.; Chen, K.; Eastgate, M.D.; Baran, P.S. Regioselective Bromination of Fused Heterocyclic *N*-Oxides. *Org. Lett.* **2013**, *15*, 792–795. [CrossRef] [PubMed]

72. Hu, W.; Zhang, F.; Chen, C.; Qi, T.; Shen, Y.; Qian, G.; Rong, Z. Metal-Free C8–H Functionalization of Quinoline *N*-Oxides with Ynamides. *Chem. Commun.* **2021**, *57*, 6995–6998. [CrossRef] [PubMed]

73. Sheldrick, G.M. SHELXT—Integrated Space-Group and Crystal-Structure Determination. *Acta Crystallogr. Sect. A Found. Adv.* **2015**, *71*, 3–8. [CrossRef] [PubMed]

74. Sheldrick, G.M. Crystal Structure Refinement with SHELXL. *Acta Crystallogr. Sect. C Struct. Chem.* **2015**, *71*, 3–8. [CrossRef] [PubMed]

75. Dolomanov, O.V.; Bourhis, L.J.; Gildea, R.J.; Howard, J.A.K.; Puschmann, H. OLEX2: A Complete Structure Solution, Refinement and Analysis Program. *J. Appl. Crystallogr.* **2009**, *42*, 339–341. [CrossRef]

76. CrysAlis Pro. *Data Collection and Processing Software for Agilent X-ray Diffractometers*; Aglient Technologies: Yarnton, UK, 2013.